Macular degeneration drug approved
The Food and Drug Administration recently approved a drug for the treatment of the wet form of age-related macular degeneration. The medication is called Eylea. The medication is manufactured by Regeneron Pharmaceuticals. At $1,850 per injection, it costs $1000 less than Genentech's Lucentis. Macular degeneration is the leading cause of severe vision loss among residents in senior living settings.